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Autoimmune diseases, such as systemic lupus erythematosus (SLE), are caused by 
a complex interaction of environmental-, genetic-, and sex-related factors. Although 
SLE has traditionally been considered independent from the microbiota, recent work 
published during the last 5 years suggests a strong connection between SLE and the 
composition of our gut commensals as one of the main environmental factors linked 
to this disease. Preliminary data have evidenced that (i) interaction of certain microbi-
al-derived molecules with specific cell receptors and (ii) the influence of certain com-
mensal microorganisms over specific immune cell subsets plays an important role in 
the pathogenesis of SLE and SLE-like diseases. In addition, epigenetic changes driven 
by certain microbial groups have been recently proposed as an additional link between 
gut microbiota and SLE. As immune responses elicited against commensal bacteria are 
deeply dependent on the composition of the latter, and as microbial populations can be 
modified by dietary interventions, identifying the precise gut microorganisms responsible 
for worsening the SLE symptoms is of crucial importance for this and other SLE-related 
diseases, including antiphospholipid syndrome or lupus nephritis. In this minireview, the 
current knowledge on the relationships between microbes and SLE and SLE-related 
diseases is compiled and discussed.
Keywords: intestinal microbiota, systemic lupus erythematosus, molecular mimicry, toll-like receptors, dietary 
intervention
GUT MiCROBiOTA AND iMMUNe SYSTeM
The term human microbiota describes the ensemble of microorganisms inhabiting our body, 
which account for 10 times more cells than our own cells, with the colon being the place in the 
body populated by the largest number of microbes. Alterations of gut microbial populations (also 
termed intestinal dysbiosis) have been associated with a large number of autoimmune and chronic 
inflammatory diseases during the last 10 years, for instance, rheumatoid arthritis, type 1 diabetes, 
inflammatory bowel disease, and recently systemic lupus erythematosus (SLE) (1, 2).
Our microbiota and immune system have co-evolved in a symbiotic way; while bacteria helps in 
digestion, presence of certain commensals triggers different signals that drive proper maturation of 
our immune system. In turn, the colon provides the right environment to host these populations. 
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Microbiota composition can be quickly modified by diet or by 
the use of certain living bacteria, known as probiotics. Intestinal 
microbiota influences the development of autoimmune diseases, 
and so this influence might be modulated through specific diets 
or with the administration of specific probiotic strains (3). 
Scientific evidence suggests that every type of microorganism 
might have a specific mechanism of action over the host immune 
system, balancing anti- and pro-inflammatory responses given 
some host factors, such as the genetic background, sex, and 
the relative abundance of a given microorganism in the whole 
microbiota (4).
In the last years, some studies have identified different micro-
bial molecules, notably located at the surface level, able to drive 
those immunological effects, among which extracellular polysac-
charides and proteins, peptides, and teichoic acids are noteworthy 
(5). The aim of the present minireview is to compile and discuss 
current evidence of the potential influence of gut microbes on 
SLE pathogeny and other related autoimmune diseases.
SYSTeMiC LUPUS eRYTHeMATOSUS AS 
A MODeL AUTOiMMUNe DiSeASe
Systemic lupus erythematosus is a complex disease with remark-
able heterogeneity in its clinical features, which includes malar 
rash, photosensitivity, and renal disorders among others. About 
half of the patients develop renal symptoms within the first year, 
and in fact kidney-specific molecules are the main target for 
immunosuppressive treatments. From the immunological point 
of view, SLE is characterized by aberrant responses at different 
levels, including uncontrolled T-cell differentiation and activa-
tion, abnormal polyclonal B-cell activation/proliferation, and 
autoantibody (IgGs) production linked to immune complex 
formation (6).
The key immunological characteristic of SLE is B-cell 
hyperactivity, which results in the production of a wide set of 
autoantibodies recognizing more than 100 different ligands, such 
as nuclear DNA or histones, ribonucleoproteins, or cardiolipin 
(7). Binding of these autoantibodies to self-antigens induces the 
formation of immune complexes, whose accumulation triggers 
molecular inflammation and leads to severe damages due to 
immunological clearance. For instance, injuries at the glomerular 
level are responsible for lupus nephritis (LN), the severity of the 
symptoms correlating with the autoantibody titers and, therefore, 
with the amount of immune complexes formed (8).
The SLE diagnosis cannot be done only on a serological basis, 
in spite of the abundant array of autoantibodies generated during 
its onset and development. SLE is diagnosed when 4 out of 11 spe-
cific criteria are fulfilled, the presence of elevated autoantibody 
titers representing only two of them (9). As B-cell hyperactivity 
underlies this auto-antigen generation, this cell type is target 
for several treatments, including monoclonal antibodies bind-
ing to specific B-cell-surface antigens (CD19, CD20, CD22) to 
trigger apoptosis/lysis, or peptides/proteins blocking binding of 
B-cell activating factors to B-cell receptors (BLyS, APRIL), thus, 
aborting maturation and proliferation (10). Remarkably, genetic 
susceptibility of the B-cell receptor gene is a factor favoring 
induction of B-cell hyperactivity by external stimuli and, there-
fore, conditioning an individual to autoimmunity (11).
In general, total IgG-class antibody titers in plasma were 
shown to be doubled in a SLE cohort regarding the controls 
(12). As it has been shown that specific IgGs raised against the 
gut microbiota displayed lower titers during active SLE episodes 
compared to inactive periods, it is conceivable to hypothesize that 
these specific antibodies are sequestered in immune complexes, 
contributing to the pathology of the disease, and opening the door 
to the involvement of certain bacteria at least in SLE relapses (12).
AUTOiMMUNe DiSeASeS, A ROLe FOR 
GUT MiCROBiOTA
The term “autoimmune disease” denotes a disorder where the 
immune system recognizes self-molecules as foreign, a process 
in which microbes may have a direct or indirect influence. Direct 
mechanisms involve growing and temporal persistence of the 
bacterium within the gut, as well as the secretion or release of 
different molecular mediators. On the contrary, indirect mecha-
nisms involve the production of epigenetic changes in human 
cells driven by the presence of the bacterium. For these reasons, 
the relationship and interactions among commensal microbes, 
immune system, and epigenetics are an emerging field of great 
interest in autoimmune disease research (13).
It should be highlighted that host sex conditions the popula-
tions inhabiting our gut, which may condition the severity of 
the symptoms, as in SLE (14). In turn, the configuration of host 
immunity at both innate and adaptive levels may condition rela-
tive abundances within those gut commensal populations, estab-
lishing a complicated feedback between relative microorganism 
abundances, host sex and the way to shape the type of immune 
responses against self and foreign antigens (15).
Commensal microbiota composition has a deep effect in terms 
of immunomodulation, whatever the immunological context 
of the host. This statement is very well illustrated by a single 
bacterial species, the segmented filamentous bacteria (SFB), 
and might be applicable to every bacterial population. SFB have 
the ability to expand the set of Th17 cells, which are involved 
in many human autoimmune diseases (16). The Th17 response 
is pathogenic in certain animal models of autoimmune diseases 
such as rheumatoid arthritis or certain IBD types, but protective 
in others such as type 1 diabetes (17–19), so the specific effect of 
a single bacterium can be either positive or negative, depending 
on the immunological status of the host. Moreover, SFB effect 
varies depending on the host sex, and so Th17 stimulation confers 
protection in females but not in males in certain murine models 
of autoimmune diseases (18, 19).
Among the different autoimmune diseases, SLE has been 
considered independent from the microbiota, with few scientific 
evidences dating back to the 1970s and 1980s. If we examine care-
fully the scientific literature, we can find some evidences, suggest-
ing a link between the presence of certain bacteria and SLE. For 
instance, cell wall deficient forms (CWD) of Propionibacterium 
acnes, Corynebacterium sp., Staphylococcus epidermis, and 
Streptococcus sp. were isolated in cutaneous lesions of patients 
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affected by SLE and other SLE-related disorders such as cutaneous 
lupus erythematosus (LE) (20). Perhaps the strongest evidence 
linking a bacterial antigen and the production of self-antibodies 
in SLE-related murine models is lipopolysaccharide (LPS) (21). 
Injection of LPS in mice induced production of anti-ds DNA 
antibodies, which were associated with an increased formation 
of immune complexes in kidneys and an exacerbation of the 
LN symptoms, including glomerular dysfunction and chronic 
kidney dysfunction (22). Regarding LPS and the generation of 
autoantibodies in murine SLE models, two studies dating from 
the mid-1970s are available (23, 24). The situation has drastically 
changed during the last 5 years with the publication of new data 
in animal models and in other related autoimmune diseases. In 
contrast to other autoimmune diseases, we have less scientific 
evidences of direct relationship between presence of commensal 
microorganisms and SLE pathogenesis. One of the first evidences 
of this potential association was the isolation of Helicobacter 
pylori in the 67% of kidney biopsies from a cohort of the SLE-
related disease LN (25). Apart from this isolated case, most of the 
microbial evidence in human SLE derives from animal models 
and in vitro experiments (26). These evidences of the involvement 
of gut microbiota on SLE and SLE-related autoimmune diseases 
are represented in Figure 1.
iNFLUeNCe OF COMMeNSAL 
MiCROBiOTA ON AUTOiMMUNe 
DiSeASeS i: MOLeCULAR MiMiCRY
The potential importance of gut bacteria in SLE may be deduced 
from the pristane-induced animal model (27). Pristane, or 
2,6,10,14-tetramethylpentadecane, is a saturated alkane present 
in shark liver oil able to induce an autoimmune disease similar 
to SLE in mice (28). Pristane administration was associated with 
different degrees of hypergammaglobulinemia in conventional 
housed and microbiota-free mice; more concisely, presence of gut 
microbiota was associated with lower IgM but higher IgA and IgG 
titers. Interestingly, production of autoantibodies was markedly 
lower and delayed in microbiota-free mice with respect to control 
mice, suggesting the existence of a microbiota-triggered stimulus 
in this murine SLE model (27).
Some microbial structures have the ability to activate autoreac-
tive T cells in certain host genetic backgrounds prone to autoim-
munity. For instance, both bacterial-DNA and different cell-wall 
components, induced the production of anti-double-stranded 
DNA (dsDNA) autoantibodies in mice (29). Molecular mimicry 
has been hypothesized as the mechanism connecting the infec-
tion of Burkholderia sp. and the exacerbation of SLE symptoms 
(30). Molecular mimicry occurs when an antibody raised against 
a given antigen is able to recognize another antigen from a dif-
ferent molecule, for instance, two different amino acid epitopes 
coming from two proteins (31). In the framework of autoimmune 
diseases, antibodies developed against bacterial antigens during 
infection are supposed to recognize self-antigens, inducing 
formation of immune complexes that contribute, for instance, to 
renal damages. On the contrary, certain bacterial molecules may 
activate autoreactive T cells.
There are several examples suggesting an involvement of 
molecular mimicry in SLE-related diseases (Table 1). Antibodies 
developed against dsDNA were shown to bind to the sequence 
ARVLWRATH from cytochrome B 561 and to sequence 
RAGTDEGFG from one of the transcription regulators from 
Burkholderia sp. (30). Another example has been documented 
in an autoimmune disease-denominated glomerulonephritis. In 
this case, the amino acid residues 72–80 of the bacterial adhesin 
FimH and the human lysosomal-associated membrane protein 
(hLAMP-2) are recognized by autoantibodies (32). FimH is a fim-
bria subunit that is present in Gram-negative enteropathogens, 
among which species from the genus Escherichia, Klebsiella, and 
Proteus. Infections by Gram-negative bacteria can be positioned 
just before glomerulonephritis onset, as well as before detection 
of autoantibodies raised against hLAMP-2 (33), suggesting a 
potential role of a bacterial infection with the generation of 
autoantibodies and with the onset of the disease. Molecular 
mimicry may also be the mechanism underlying the activation 
of the T-cell population reactive against certain SLE antigens such 
as Ro60, a protein binding to small, non-coding RNAs termed “Y 
RNAs” (34). Although authors claimed that multiple commensal 
microbial peptides are able to activate T cells reactive against 
Ro60, no further information on the amino acid sequences is 
available.
Molecular mimicry involving bacterial molecules is also 
involved in the generation of autoantibodies in other autoim-
mune diseases, such as antiphospholipid syndrome (APS) (16). In 
this disease, certain surface molecules such as lipoligosaccharides 
from Campylobacter jejuni are believed to mimic gangliosides 
from the human nerves, generating and maintaining the pro-
duction of autoantibodies. Notably, certain bacterial sequences 
mimic the self-targets of aPLs autoantibodies, such as TLRVYK 
sequence from β2-glycoprotein 1, which shows homology to 
surface proteins from Haemophilus influenzae, Neisseria gonor-
rhoeae, or the tetanus toxoid (16). Several antibodies developed 
against pneumococcal antigens showed cross-reactivity against 
self-antigens, notably dsDNA (35). Eight out of those antibodies 
were also able to recognize bacterial exopolysaccharide, DNA, 
and histones, as well as glomerular structures such as some 
renal proteins (36). Additional evidence of molecular mimicry 
underlying bacterial infections are the antibodies raised against 
CpG DNA of Escherichia coli and the cholera toxin B of Vibrio 
cholerae, which promoted production of DNA autoantibodies in 
mice models (37).
iNFLUeNCe OF COMMeNSAL 
MiCROBiOTA ON AUTOiMMUNe 
DiSeASeS ii: SUPeRANTiGeNS
Superantigens are a class of toxins produced by many bacteria 
and viruses, which have the capacity to massively activate 
immune cells, by binding simultaneously to major histocom-
patibility complex class II proteins on antigen-presenting cells, 
and to the specific T-cell receptors on activated T cells (38). 
Superantigens are involved, among other pathological processes 
such as bacterial toxic shocks, in inducing autoimmunity by 
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activating self-reactive T cells. Different bacterial molecules act 
as antigens and are involved in the trigger and progression of 
many autoimmune diseases. For instance, relapses of granulo-
matosis, an autoimmune disorder affecting kidneys, is directly 
correlated with a previous infection of superantigen producing 
Staphylococcus aureus strains in the upper respiratory tract (39). 
In this process, the adhesion properties of the staphylococcal 
acid phosphatase have a pivotal role through its binding to 
endothelial cells (40).
It should be mentioned that although molecular mimicry and 
superantigen involvement are well-explained in animal models, 
further research is needed in order to identify specific interac-
tions between microbiota and immune system responsible for the 
generation and maintenance of autoreactive T cells in the human 
host, as well as for the production of autoantibodies.
MeTAGeNOMiC STUDieS SHOw AN 
iNTeSTiNAL DYSBiOSiS ASSOCiATeD 
wiTH SLe
During the last years, high-throughput technologies have made it 
possible to deeply characterize the composition of the microbial 
populations inhabiting our gut, and to associate certain compo-
sition patterns, or the absence/presence of certain species with 
different disorders. One of the first in  vivo studies, suggesting 
FiGURe 1 | evidences of the role of the commensal microbiota in SLe pathogenesis. (A) Antibody titers were increased in SLE patients, being those 
recognizing the gut microbiota decreased during the disease episodes, probably after binding to certain bacterial members (12). (B) Cell wall deficient forms (CWD) 
of commensal bacteria were isolated from skin lesions in LE patients (20), and Helicobacter pylori was isolated in the 67% of kidney biopsies from a LN cohort (25). 
(C) In the pristane animal model of SLE, production of autoantibodies was lower and delayed, in germ-free versus control mice (27). (D) Injection of LPS in mice 
induced production of anti-dsDNA antibodies (22).
a relationship between alterations in the gut microbiota and a 
female-biased autoimmune disease, was published 4  years ago 
using a model of type 1 diabetes, the non-obese diabetic (NOD) 
mice (it should be noted that in humans the type 1 diabetes is not 
sex-biased) (18, 19). In this work, gut colonization by the Th17 
inducing SFB was associated with the absence of development of 
type 1 diabetes. Moreover, knock out lines of the NOD mice lack-
ing the myeloid differentiation primary response gene (MyD88), 
which is an adaptor molecule downstream the signaling pathway 
of certain toll-like receptors (TLRs), resulted in changes on the 
microbiota composition and conferred a protective effect on type 
1 diabetes (41). These results strongly suggested a role for the 
microbiota composition in the context of female-biased autoim-
mune diseases, such as SLE or the APS.
In the moment where this manuscript was drafted, two 
metagenomic studies concerning SLE were available, one in the 
murine MRL/lpr model and the other in humans (1, 2, 42). From 
a microbial point of view, the situation is slightly different in 
humans when compared to mice. MRL/lpr mouse females showed 
higher numbers of the families Lachnospiraceae and Bacteroidetes, 
and lower numbers of Bifidobacteriaceae and Erysipelotrichaceae 
(42). Overall, the human situation was summarized by decreases 
on the Firmicutes/Bacteroidetes ratio in the samples correspond-
ing to SLE patients (1, 2). Decreases in this ratio have also been 
observed in human type-2 diabetes and in Crohn’s disease when 
compared to control populations (43, 44).
TABLe 1 | Molecular mimicry between molecules of bacterial origin and 
host structures.
Bacterial 
species
Bacterial 
molecule
epitope Host target
Burkholderia 
sp.
Cytochrome B 561 ARVLWRATH dsDNA
Burkholderia 
sp.
Transcription 
regulator
RAGTDEGFG dsDNA
Escherichia sp. FimH Residues 72–80 hLAMP-2
Klebsiella sp. FimH Residues 72–80 hLAMP-2
Proteus sp. FimH Residues 72–80 hLAMP-2
– – Microbial peptides Ro60
Campylobacter 
jejuni
Lipoligosaccharides – Gangliosides
Haemophilus 
influenzae
Surface proteins TLRVYK β2-glycoprotein 1
Neisseria 
gonorrhoeae
Surface proteins TLRVYK β2-glycoprotein 1
Tetanus toxoid Surface proteins TLRVYK β2-glycoprotein 1
Streptococcus 
pneumoniae
Exopolysaccharide – dsDNA, histones, 
renal proteins
Escherichia coli Genomic DNA CpG islands dsDNA
Vibrio cholerae Cholera toxin B – dsDNA
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Being more precise, pronounced increases in the 
Bacteroidetes/Prevotellaceae groups, and decreases of the 
Lachnospiraceae/Ruminococcaceae members were observed in 
the human SLE cohort (1, 2). Some of the species belonging to 
the Lachnospiraceae family comprise butyrate producers, such 
as Roseburia sp. or Butyrivibrio sp. Butyrate production in the 
human gut is relevant since it promotes differentiation of Tregs, 
a T-cell type able to suppress any kind of pro-inflammatory 
response (45).
Whereas the same observations were reported for Bacteroidetes 
populations in mice, Lachnospiraceae and Ruminococcaceae 
families showed opposite behaviors. This might be a direct con-
sequence of the mutation carried by MRL/lpr mice (Faslpr), which 
makes them deficient in Fas-mediated signaling. This genetic 
deficiency makes T cells refractory to butyrate-induced apopto-
sis, and this in turn may have a consequence in the composition 
of the intestinal microbiota (46). Decreases in members of the 
family Lachnospiraceae have been proposed as a parameter for 
monitoring disease activity in inflammatory bowel disease, and 
it remains to be validated whether this can also be applied to SLE 
(47). For this purpose, further metagenomic studies, involving 
larger cohorts, will be needed.
iNFLUeNCe OF MiCROBiAL DNA 
THROUGH TOLL-LiKe ReCePTORS 7 
AND 9
One of the factors that has delayed the study of the microbial 
influence on SLE pathogenesis was the absence of correlation 
between symptoms and breeding conditions in murine models, 
as this strongly affect the microbial load of the animals (4). 
Some scientific studies performed in the last years suggested an 
important role for two receptors of the innate immune system, 
TLR7 and TLR9, in SLE pathogenesis; the involvement of TLR4 
being also under investigation (48). TLRs recognize specific 
microorganism ligands, and are one of the first lines of defense 
against external threats. Among the 10 TLRs identified so far in 
humans (12 in mice), TLR7 recognizes single-stranded viral RNA 
(ssRNA), whereas TLR9 recognizes both bacterial/viral dsDNA. 
The main TLR4 ligand is LPS, but it can also recognize different 
proteins such as viral glycoproteins, heat-shock proteins, and 
fibronectin, among others.
Expression of both TLR7/9 genes is increased in SLE patients 
when compared to healthy controls and this expression level corre-
lates positively with levels of typical serological pro-inflammatory 
markers, such as IL-6, IFN-gamma, and TNF-alpha (49). Self-
RNA and self-DNA are main targets for autoantibody generation 
in autoimmune diseases, and the complex nucleic acid – antibody 
seems to contribute, through an altered recognition by TLR7 and 
TLR9, to the aberrant immune responses observed in SLE (50). 
This includes activation and expansion of autoreactive B and T 
cells (51); in fact, triggering of autoreactive memory B cells by 
bacterial/viral DNA through the action of TLR9 has been pro-
posed to be implicated in SLE relapses (52).
Results from animal models have shown that alterations of the 
innate immune system through the action of specific receptors, 
such as TLRs, correlate with SLE symptoms. Duplication of TLR7 
gene in a SLE mouse model (Yaa mice), has been shown to be 
directly related to the disease by an excessive auto-RNA signaling 
through this receptor (53). In fact, the number of TLR7 molecules 
is directly related to the risk of the development of SLE in mice, 
supporting the role of the innate immune system in the onset of 
this disease. Duplication or overexpression of the tlr7 gene resulted 
in increased titters of RNA-specific autoantibodies, whereas defi-
ciencies in the TLR9 signalization pathway involved increased 
production of anti-DNA/anti-chromatin antibodies (54).
A ROLe FOR THe viROMe iN SLe?
An important part of the microbial populations inhabiting our 
body are virus and bacteriophages, which are referred collec-
tively as the human virome. The first evidence suggesting that 
viruses were involved in the triggering and development of SLE 
was the higher IFN-α levels found in the blood of a SLE cohort 
(55). Infection by Epstein–Barr virus (EBV) has been correlated 
in LN through a higher production of anti-Sm antibodies, 
which are autoantibodies directed against seven proteins of 
different ribonucleoproteins (56). Certain experimental stud-
ies indicated a connection between an abnormal immune 
response to EBV and SLE; more concisely, it has been observed 
that SLE patients developed specific anti-EBV IgG antibodies 
that were absent in healthy controls, and vice versa (57). From 
an epidemic point of view, EBV infection is associated with a 
higher risk of developing SLE and other autoimmune diseases, 
such as multiple sclerosis (58). As EBV infects B cells (and other 
immune cells) inducing the production of pro-inflammatory 
cytokines, this fact and an aberrant immune response to this 
virus could be linked to SLE. Further research will elucidate the 
precise role of viruses in SLE.
FiGURe 2 | Main mechanisms of potential influence of the intestinal microbiota in the framework of autoimmune diseases. (A) The immunomodulatory 
effect of the intestinal microbiota is highly dependent on its composition and on the immunological status of the host. Some bacteria trigger downstream effector 
responses, such as Th1, Th17, or Th2, whereas other acts by expanding the subset of regulatory T cells. Expression of certain receptors recognizing bacterial and 
viral DNA, mainly TLR7 and TLR9, is increased in the context of SLE. (B) Superantigens are molecules activating both innate (represented by a dendritic cell) and 
adaptative immunity (represented by a T-cell clone), being this the mechanism of action of some pathogens notably at the level of the upper respiratory tract. (C) 
Infection of the Epstein–Barr virus in B cells could be responsible for the increased levels of interferon gamma observed in the serum of certain SLE patients. IFNγ is 
produced mainly by natural killer and natural killer T cells during innate immune response and by CD4+ Th1 and CD8+ cytotoxic T lymphocyte cells during adaptative 
immune response. (D) Autoreactive B and T cells may be activated by antigens from bacterial origin leading to production of auto antibodies. This similarity between 
certain bacteria antigens, such as peptides (represented by the gray sphere) and autoantigens at the molecular level, is denominated molecular mimicry. Clearance 
of immune complexes is directly related to damages at the kidney level. In a context of autoimmunity, increased production of autoantibodies involves higher 
formation of such complexes.
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DieT, MiCROBiOTA, AND SLe
From a nutrition point of view, most of the work in SLE has been 
traditionally focused on the immunomodulatory effect of single 
dietary components with a demonstrated role on the immune 
system. Although very little is known about the impact of diet 
on microbiota in SLE subjects, there is some scientific evidence 
supporting the hypothesis that some of the dietary impact on 
SLE pathology could be achieved through modulation of the gut 
microbiota (4). Currently, there is not enough information to 
estimate if a dietary intervention could work on preventing SLE 
relapses. However, evidence from other diseases with an associ-
ated dysbiosis showed the impact of several dietary components 
in balancing certain microorganism populations, which may be 
applied to SLE.
It has been reported that a diet restricted in carbohydrates 
or fat, balanced the gut microbiota increasing the proportion of 
Bacteroidetes in obese subjects with high Firmicutes/Bacteroidetes 
ratios (compared to lean controls) (59). In this sense, Western 
diets, characterized by their richness in animal proteins and 
saturated fats, have also been correlated with a greater abundance 
of Bacteroidetes (60). On the contrary, diets supplemented with 
whole grains produced an increase in Firmicutes/Bacteroidetes 
ratio (61), and the administration of a low-fat/high-fiber diet has 
been correlated positively with Firmicutes (62). In consonance 
with these findings, lower levels of Bacteroidetes were observed 
in African children with a long-term consumption of diets rich in 
whole grains, dietary fibers, and vegetables supporting the health 
benefits of whole grains by means of microbiota modulation (63).
To the best of our knowledge, there is no intervention study 
in the literature to test the effects of the amount and type of fats 
included in diet on SLE microbiota. A descriptive work from 
our research group did not support the association between fats 
or saturate fatty acids at moderate amounts in a well-balanced 
diet and fecal microbiota in a SLE cohort (64). It is noteworthy 
that some of the effects ascribed to fat intake are dose- and food-
dependent, i.e., they show different effects depending on the food 
where they are found. For instance, presence of orange juice in 
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a high-fat meal decreased the impact of fats on oxidative stress 
(65). For this reason, some authors have suggested studying the 
interactions between the different components of a meal, rather 
to focus on the effects of a single ingredient (66).
Recently, we have reported on the association between the 
intake of fruits, such as oranges and apples, and decreases in 
specific microorganism populations in SLE patients (64). It 
is important to consider that these fruits are natural dietary 
sources of polyphenols and fibers with a high potential to 
modulate microbiota. Specific phenolic compounds like 
dihydrochalcones from apples, along with dietary fiber, are 
degraded by bifidobacteria promoting its growth (64, 67, 68). 
These kinds of changes could be of special interest for SLE 
patients given the immunomodulatory effect attributed to 
some strains of the genus Bifidobacterium (69). For instance 
Bifidobacterium bifidum LMG13195 strain promoted the 
expansion of Treg cells, a T-cell population favoring mucosal 
homeostasis (70, 71). Other works showed positive associations 
between dietary flavones and the levels of Blautia sp., a member 
of the Clostridium cluster XIVa. As this microorganism is also 
involved in the expansion of Treg cells, promoting its growth 
through the diet may be interesting in order to maintain/restore 
immune homeostasis (72).
Finally, it is very interesting to mention the effect of vitamin A 
in the diet. A dietary intervention with vitamin A in animal mod-
els has returned improvements of the SLE pathogenesis, notably 
in the reduction of both proteinuria and glomerulonephritis, 
and has been shown to globally reduce the LN symptoms (73, 
74). Another dietary intervention study showed that the intake 
of retinoic acid, which is the active form of vitamin A (retinol), 
restored the lactobacilli levels that were decreased during SLE 
development in mice (42). This is not the only known effect 
of vitamin A on our gut commensals, as the growth of SFB is 
influenced by the levels of this vitamin, and as stated before this 
bacterial group appears to play crucial roles in the development 
of several SLE-like diseases through the expansion of the Th17 
cell subset (4).
PeRSPeCTiveS
In this review, we have shown that gut bacteria composition 
may have a role in SLE as deduced from SLE-related autoim-
mune diseases, female-biased or not. Potential mechanisms 
involved are summarized in Figure  2. With the incoming of 
novel metagenomic and metatranscriptomic studies focused on 
SLE microbiota, we will undoubtedly describe the precise role 
of the different microbial population on SLE and other autoim-
mune diseases. Altered microbial colonization in the gut (such as 
abnormal Firmicutes:Bacteroidetes ratio) might contribute to a 
misbalanced immune response responsible for the triggering or 
the relapses of the disease. In this sense, it might be hypothesized 
that excessive Bacteroides signaling through our innate immune 
system might have a role in SLE pathogenesis, although this is a 
speculative statement that deserves further investigation.
Scientific results evidenced how some surface-associate pro-
teins and DNA/RNA from both bacteria and viruses are wrongly 
recognized by the immune system. This molecular mimicry lead 
autoreactive immune cells to attack self-structures in response 
to bacterial exposure. Therefore, future research will elucidate 
whether SLE patients also develop antibodies against the com-
mensal microbiota, and if molecules derived from are able to 
activate autoreactive T cells through molecular mimicry (1, 2).
Dietary interventions will undoubtedly be of great importance 
to generate new designs of functional foods focused to correct 
dysbiosis observed in SLE and other autoimmune diseases. 
For instance, administration of specific commensals, used as 
probiotics, might be designed to specifically treat SLE. Use of 
microorganisms can be dual, as they are able to both displace 
undesired populations and modulate host immune responses. 
In this sense, the usefulness of experimental treatments such 
as fecal microbiota transplantation separated and normalized 
from the rest of feces components through density gradients, or 
application of immunomodulatory peptides obtained from our 
commensal microbiota might be important in the future.
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